Cimzia(certolizumab pegol)
Cimzia (certolizumab pegol) is an antibody pharmaceutical. Certolizumab pegol was first approved as Cimzia on 2008-04-22. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tumor necrosis factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cimzia
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cimzia | Biologic Licensing Application | 2024-09-19 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
167 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 4 | 2 | 22 | 7 | 10 | 45 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 2 | 20 | 7 | 9 | 42 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 4 | 17 | 3 | 8 | 35 |
| Spondylitis | D013166 | — | M46.9 | 3 | 1 | 5 | 1 | 3 | 13 |
| Spondylarthritis | D025241 | — | — | 3 | 1 | 5 | 1 | 2 | 12 |
| Axial spondyloarthritis | D000089183 | — | — | 3 | — | 3 | 1 | 2 | 9 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | — | 1 | — | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | 1 | — | 1 |
| Anterior uveitis | D014606 | EFO_1000811 | — | — | — | — | 1 | — | 1 |
| Iridocyclitis | D015863 | — | H20 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 3 | 5 | — | 3 | 11 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 3 | — | 2 | — | 3 | 8 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | 2 | 1 | 2 | — | 2 | 7 |
| Fistula | D005402 | — | — | — | — | 1 | — | 1 | 2 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | 1 | — | — | 1 |
| Non-radiographic axial spondyloarthritis | D000089202 | — | M45.A | — | — | 1 | — | — | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | — | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | — | — | 1 |
| Necrosis | D009336 | — | — | — | — | 1 | — | — | 1 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | — | — | — | 1 | 1 |
| Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
| Collagen diseases | D003095 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Certolizumab pegol |
| INN | certolizumab pegol |
| Description | Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201831 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08904 |
| UNII ID | G6ADW90R16 (ChemIDplus, GSRS) |
Target
Agency Approved
TNF
TNF
Organism
Homo sapiens
Gene name
TNF
Gene synonyms
TNFA, TNFSF2
NCBI Gene ID
Protein name
tumor necrosis factor
Protein synonyms
APC1 protein, Cachectin, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, TNF-alpha, tumor necrosis factor ligand 1F, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha, tumor necrotic factor alpha
Uniprot ID
Mouse ortholog
Tnf (21926)
tumor necrosis factor (P06804)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,350 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cimzia
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
108,867 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use